Major Goals For ATAI: $175M Secured In Term Loan Facility, Plus Q2 Earnings Report
Atai Life Sciences: Capital Raise, Share Options, Cathie Wood And More On Biotech Psychedelics Leader
Atai Life Sciences Posts Earnings for Q1 2022, Advancing Key Milestones In Psychedelic Drug Development
Can Ketamine For Depression Be Improved? New Study Will Look Into Ketamine Analog Arketamine